In 2000, the new millennium brought with it a new dental implant surface. Fifteen years later, Nobel Biocare's TiUnite has built a reputation for success and is one of the most clinically researched implant surfaces in the world. And, after more than 15 million purchases of implants featuring TiUnite, it’s reportedly become one of the most sought after as well.
For decades, the staged Brånemark osseointegration protocol was the norm for dental implant placement. Then, in the 1990s, studies were published showing a one-stage procedure with early or even immediate loading was also a safe option.
This new procedure reduced treatment times and avoided a second surgery – great for the patient. But the impact on the bone-to-implant surface was a challenge. A new surface that could speed up bone apposition was needed. The solution was TiUnite.
Faster, stronger osseointegration
The TiUnite implant surface was designed to enhance osseointegration, even under the most challenging conditions. It’s created by using anodic oxidation to make a thickened layer of moderately rough titanium oxide. TiUnite’s micropores reportedly result in stronger osseointegration compared with machined surfaces. It has been proven that bone grows into the pores of TiUnite, leading to strong interlocking between the surface and the bone.
Increased survival rates
Since it hit the market 15 years ago, moderately rough surfaces have virtually replaced the original machined surface. The shift to TiUnite from machined implants is said to have shown a clear decrease in early failures, especially in areas with poor bone density.TiUnite also reportedly makes immediate loading possible more frequently and with superior outcomes. As a result, TiUnite now features on all Nobel Biocare’s implant systems.
Those looking for further support for TiUnite’s efficacy can refer to substantial clinical evidence. In the 15 years since its launch, TiUnite is said to have become of the most frequently used and clinically researched implant surfaces. It has now featured in more than 270 clinical studies looking at 45,000 implants in more than 13,000 patients with up to 12-year follow-up.
To find out more about TiUnite, visit nobelbiocare.com/TiUnite.